Barbora Orlikova-Boyer, Anne Lorant, Sruthi Reddy Gajulapalli, Claudia Cerella, Michael Schnekenburger, Jin-Young Lee, Ji Yeon Paik, Yejin Lee, David Siegel, David Ross, Byung Woo Han, Thi Kim Yen Nguyen, Christo Christov, Hyoung Jin Kang, Mario Dicato, Marc Diederich
BACKGROUND: Despite advancements in chronic myeloid leukemia (CML) therapy with tyrosine kinase inhibitors (TKIs), resistance and intolerance remain significant challenges. Leukemia stem cells (LSCs) and TKI-resistant cells rely on altered mitochondrial metabolism and oxidative phosphorylation. Targeting rewired energy metabolism and inducing non-apoptotic cell death, along with the release of damage-associated molecular patterns (DAMPs), can enhance therapeutic strategies and immunogenic therapies against CML and prevent the emergence of TKI-resistant cells and LSC persistence...
May 4, 2024: Biomarker Research